Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Intro slide
- Outline of talk
- Practice parameter - guidelines
- Practice recommendation
- Potentially reversible conditions
- Potentially reversible primary aetiologies
- The decreasing prevalence of reversible dementias
- Treatable cause (?) - 1
- Treatable cause (?) - 2
- Reason for MRI in evaluation of dementia
- "Treatable causes" with imaging
- The 'exclusionary' approach to dementia
- The 'inclusionary' approach
- Changing indications for imaging
- Basic MRI protocol
- The spectrum of FTLD
- The need to look at all slices
- Subcortical vascular cognitive impairment
- CADASIL
- Specific type of vascular dementia
- Thalamic lesions in vascular dementia
- CJD: sporadic and variant
- CBD
- PSP
- Medial temporal lobe (MTL) in AD
- Alzheimer's Disease: Braak stages
- Hippocampal volume
- The 'fingerprint' of AD
- MTL atrophy: visual rating
- Visual rating of MTA
- Visual rating of MTA - examples
- Visual rating of MTA - reliability
- Visually and volumetrically estimated MTA
- Correlation with pathology
- Assessment MTL atrophy - qualitative rating
- Volumetry of MTA
- Visual rating and volumetry of the MTL
- Diagnostic value of MTA - AD vs. ND
- Diagnostic value of MTA - AD vs. C
- MTA assessment in routine practice
- MTA on MRI in dementia with LB and VaD
- Study results
- Patterns of cerebral atrophy in dementia with LB
- MRI volumetric study of dementia with LB
- Temporal lobe on MRI in PD with dementia
- Presenile/senile difference in hippocampal atrophy
- Analysis using voxal based morphometry
- MTA in MCI
- MTA predicts AD in patients with MCI
- MTA predicts dementia in patients with MCI
- MTA visual score
- Conclusions
Topics Covered
- Changing role of structural imaging in dementia
- Current diagnostic use
- Sensitivity and specificity
- Identifying biological markers for disease
- Examples from clinical practice
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Scheltens, P. (2007, October 1). Neuro-imaging in dementia: using MRI in routine work-up [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/HHYE5858.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Philip Scheltens has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.